secwatch.observer — SEC 8-K summary
======================================

Issuer:     Arbutus Biopharma Corp (ABUS)
CIK:        0001447028
Form:       8-K
Filed at:   2022-11-09T23:59:59+00:00
Accession:  0001171843-22-007260
Event type: earnings
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.02, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Arbutus reports Q3 net loss $17.6M, discontinues AB-836 capsid inhibitor, cash runway into Q2 2024
--------------------------------------------------------------------------------

- Net loss $17.6M ($0.12/share) vs $24.2M loss Q3 2021; revenue $6.0M (+$2.7M YoY) on Qilu license income.
- Cash, equivalents and investments $190.2M; 2022 net cash burn forecast $90-95M; runway into Q2 2024.
- Discontinued AB-836 (oral capsid inhibitor) due to ALT elevations in healthy volunteer arm of Phase 1 trial.
- AB-729 off-treatment data: HBsAg and HBV DNA suppressed up to 44 weeks post-therapy; no relapses in 9/9 patients.
- On-track to complete IND-enabling studies for AB-161 and AB-101, and nominate pan-coronavirus Mpro candidate by year-end.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1447028/000117184322007260/0001171843-22-007260-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1447028/000117184322007260/f8k_110922.htm
  HTML page:      https://secwatch.observer/filing/0001171843-22-007260

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer